Addressing an Unmet Need

Inhibitors—neutralizing antibodies directed against clotting factor therapies—remain a significant complication in hemophilia management. They render conventional replacement strategies ineffective and leave patients vulnerable to recurrent and potentially severe bleeding episodes. Approximately one in five patients with hemophilia A and a smaller proportion of those with hemophilia B develop inhibitors, often resulting in higher morbidity and treatment burden.

The newly expanded indication positions marstacimab as a therapeutic option for individuals weighing at least 35 kg, offering an alternative to more complex regimens such as bypassing agents, which are typically administered intravenously and require frequent dosing.

Once-Weekly Subcutaneous Administration

Marstacimab distinguishes itself through a simplified mode of delivery. Administered as a once-weekly subcutaneous injection, it reduces reliance on intravenous infusions and eliminates the need for routine laboratory monitoring associated with many traditional therapies. This ease of administration may improve adherence and quality of life, particularly for adolescents and patients with difficult venous access.

Notably, it is currently the only therapy in the European Union approved for once-weekly subcutaneous prophylaxis in both hemophilia A and B populations, regardless of inhibitor status.

Phase 3 Data Demonstrate Significant Bleeding Reduction

The EC’s decision is supported by data from the global Phase 3 BASIS trial, which evaluated marstacimab in patients aged 12 years and older with severe hemophilia A or moderately severe to severe hemophilia B, including those with inhibitors.

Results showed a substantial reduction in bleeding events compared with on-demand treatment using bypassing agents. Patients receiving marstacimab experienced a roughly 93% decrease in annualized bleeding rates (ABR), highlighting both statistical and clinical superiority over prior standard care. Improvements were consistent across multiple bleeding categories, including spontaneous bleeds and joint-related events.

Long-term findings from an open-label extension study further reinforce these results. Over extended follow-up—exceeding four years in some cases—bleeding rates remained low, suggesting sustained efficacy with continued therapy.

Safety Profile and Considerations

The safety profile observed in the Phase 3 study was consistent with earlier clinical findings. Common adverse events included injection-site reactions, headache, itching, rash, and hypertension. Thrombotic events were reported as the most serious complication, underscoring the need for careful patient monitoring and risk assessment.

A Novel Mechanism of Action

Unlike replacement therapies that supply missing clotting factors VIII or IX, marstacimab works by targeting tissue factor pathway inhibitor (TFPI), a natural regulator of coagulation. By inhibiting TFPI, the therapy aims to restore hemostatic balance and promote clot formation through an alternative pathway. This mechanism is particularly valuable in patients with inhibitors, where traditional factor-based strategies fail.

Broader Regulatory and Development Landscape

The EC authorization applies across all EU member states as well as several additional European Economic Area countries. Outside Europe, regulatory activity continues. In the United States, marstacimab is already approved for prophylaxis in certain patients without inhibitors, and a supplemental application to expand its use—particularly in younger populations and those with inhibitors—is under priority review, with a regulatory decision anticipated in 2026.

Ongoing studies, including pediatric trials and long-term extension programs, are expected to further define the therapy’s safety and efficacy across a broader range of patient populations.

Implications for Clinical Practice

The expanded approval of marstacimab represents a meaningful advance for patients with hemophilia complicated by inhibitors—a group historically underserved by existing therapies. By combining robust bleed protection with convenient administration, the therapy may shift treatment paradigms and reduce disease burden.

Clinicians may now consider an additional prophylactic option that simplifies management while delivering durable clinical benefit. As real-world data emerge and further studies are completed, marstacimab is likely to play an increasingly prominent role in comprehensive hemophilia care.